This narrative review comprehensively addresses pregnancy-related considerations in RA patients, prioritizing meticulous disease management with pregnancy and breastfeeding-compatible drugs in line with the latest recommendations and registry data. The focus remains on evaluating glucocorticoids, conventional, and biological disease-modifying drugs for compatibility during pregnancy and breastfeeding. Additionally, the evolving landscape of targeted synthetic drugs during pregnancy is explored, providing insights into the latest developments in rheumatological care.
Keyphrases
- rheumatoid arthritis
- preterm birth
- pregnancy outcomes
- end stage renal disease
- preterm infants
- healthcare
- newly diagnosed
- disease activity
- chronic kidney disease
- palliative care
- drug induced
- cancer therapy
- quality improvement
- machine learning
- ankylosing spondylitis
- artificial intelligence
- pain management
- single cell
- big data
- drug delivery
- deep learning
- health insurance